ASCO research highlights: First KRAS inhibitor and CAR T cell therapy for CLL

June 28, 2019 | City of Hope

At ASCO, City of Hope presented on a number of topics, but some of the most noteworthy involved the first KRAS inhibitor to show anti-tumor activity and the use of CAR T cell therapy in chronic lymphocytic leukemia.

Continue Reading

City of Hope to offer CAR T cell therapy for patients with the most common type of NHL

May 4, 2018 | Letisia Marquez

City of Hope recently announced that it is one of the first treatment centers certified in the United States to administer tisagenlecleucel CAR T cell therapy to adult patients with relapsed or refractory large B cell lymphoma.

First FDA-approved CAR T Therapy for Some Types of ALL to Be Offered at City of Hope

April 13, 2018 | Letisia Marquez

City of Hope recently announced that it is a certified treatment center to administer tisagenlecleucel CAR T cell therapy – the first CAR T cell therapy approved by the U.S. Food and Drug Administration – to patients.